The purpose of this analysis was to examine the ability of the MOS-HIV (Medical Outcomes Study-Human Immunodeficiency Virus) Health Survey and the EuroQol Group's EQ-5D questionnaire to discriminate between subjects in predefined disease-severity groups on the basis of clinical-indicator status (i.e., CD4 cell counts, HIV type 1 [HIV-1] RNA copies). This study used medical records of and instruments completed by 242 HIV-infected patients. The ability of the health-related quality-of-life instruments to discriminate between subjects stratified by disease severity was assessed by means of receiver-operating characteristic (ROC) curve analysis. The EQ-5D ( ) and MOS-HIV physical health summary (PHS) scores ( ) were able to P ! .05 P ! .01 discriminate between groups of subjects stratified by disease severity on the basis of either CD4 cell counts or HIV-1 RNA copies. These findings provide further evidence of the validity of the use of EQ-5D and the MOS-HIV questionnaire and suggest that they may be practical tools for the monitoring of health status from the HIV-infected patient's perspective.
with the significant progress in the medical management of HIV infection and its consequences.
The improvements in mortality rates and in the duration of AIDS-free survival for HIV-infected individuals have been dramatic [6, 7] . Hence, from the early 1980s, when most HIV-infected persons were destined to progress rapidly to AIDS and death, to the late 1990s, in which HIV-infected persons were likely to live longer and more productive lives, the HRQOL measurement task had changed considerably. Persons infected with HIV are not only concerned with a treatment's ability to extend life but also with the quality of the life they are able to lead [8] . The latter is particularly important, because the longevity of the therapeutic effectiveness of antiretrovirals is indeterminate, and adverse effects are common with their use [9] . Therefore, assessments of the impact of HIV infection and its treatment on patient-reported health outcomes are extremely important. The revised treatment guidelines for HIV infection [10] , released in January 2000 by the National Institute of Allergy and Infectious Diseases, recommend that practitioners consider a patient's HRQOL when selecting a treatment regimen to achieve the clinical goal of virus suppression. With this growing emphasis on HRQOL, clinicians and researchers must better understand how to measure it in HIV-infected patients. One means of testing the measurement characteristics of an HRQOL instrument is to assess its ability to discriminate between groups known to differ on other indicators of health (e.g., laboratory values and clinician assessments) [11] . This discriminative ability is a measure of the instrument's construct validity [12] .
The intent of this analysis was to explore the relationships between HIV-infected/AIDS patients' clinical health indicators (i.e., CD4 cell counts and HIV-1 RNA copies [virus loads]) and their HRQOL, as measured by means of the Medical Outcomes Study-HIV Health Survey (MOS-HIV) and the EuroQol Group's questionnaire (EQ-5D). The specific aim was to assess the ability of these instruments' scores to discriminate between subjects in predefined disease severity groups on the basis of clinical-indicator status. Although self-reported HRQOL assesses constructs that transcend laboratory clinical parameters, substantiation of the hypothesized relationships between the 2 types of health indicators provides evidence of the validity of the measurement tools.
PATIENTS AND METHODS

Subjects.
Data were collected at an HIV specialty clinic from June through August 1999. A sample size of 250 patients, or ∼25% of the patient population at the clinic, was chosen. The convenience sampling method was used [13] . Clinic staff recruited potential participants as they signed in for routine clinical visits. To encourage participation, patients were offered US$5 for completion of the study questionnaire. Subjects were у18 years of age and had clinically documented HIV infection. To be included in the study, subjects needed to be able to read, understand, and successfully complete the English-language study documents.
Health-related quality-of-life measures. Two existing patient-reported health status measures were used to assess HRQOL in this study. Subjects were provided with the MOS-HIV and EQ-5D questionnaires for self-administration during a routine clinic visit.
MOS-HIV.
General and condition-targeted health status instruments that have evolved from the measures developed for use in the Medical Outcomes Study (MOS) have been used to assess HRQOL, as reported by patients with HIV disease [14, 15] . The 34-item MOS-HIV Health Survey was based on items from the MOS 20-Item Short Form Health Survey (SF-20) [16] . The SF-20 survey is a generic health-status instrument that uses 6 scale scores (i.e., general health perceptions, physical function, role function, social function, pain, and mental health). Concepts believed to be significant in HIV disease (i.e., energy/fatigue, cognitive functioning, health distress, and quality of life) were added to the SF-20 survey in the development of the MOS-HIV survey.
In addition to 10 multi-item scale scores, 2 summary scores (the physical health summary [PHS] and the mental health summary [MHS]) can be calculated from the MOS-HIV scales [17] . The MOS-HIV also contains a single item that assesses health transition, which is not included in the multi-item scales [16, 17] or reported in this study. The MOS-HIV scale and summary scores range from 0 to 100; higher scores represent better functioning and well being. The MHS and PHS are scored by means of a method that transforms the scores to a standardized scale (t-scores) with a mean of 50 and a SD of 10 in the sample in which the summary scores were developed [17] . This standardized scoring of the summary scores provides a means of comparing results to those of other studies in which the MOS-HIV was used. Patients with mean PHS and MHS scores above or below 50 can be interpreted as having, respectively, better or worse HRQOL than the HIV-infected patient sample from which the summary measures were developed.
Although it has its limitations [16, 18] , there is extensive evidence to support the reliability, construct validity, and responsiveness of the MOS-HIV scale and summary scores. It has been one of the most widely used instruments among those used in studies of persons with HIV [16] .
EQ-5D. The EuroQol Group's EQ-5D questionnaire is a preference-based measure that yields a single number, or health index score, to represent the respondent's point-in-time subjective health status, and it incorporates a preference value for that overall health state [19] . It contains a descriptive system that assesses 5 dimensions of health (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression) at 3 levels, which range from "no problem" to "extreme problem." A preference value for the subject's self-reported health status is assigned from a population-based valuation system.
Because of the absence of North American valuation of health states, the EQ-5D health state values were assigned according to the Measurement and Valuation of Health Research Group (MVH) A1 "tariff" [20] , which was derived from a survey of the general population in the United Kingdom. The health index scores are on a scale in which full health and death are denoted by 1 and 0, respectively. Some severe health states are denoted by negative values, which indicate that the health states are considered to be worse than death. In addition, the EQ-5D allows patients to assign a value to their own health states using a vertical, 20-cm visual analog scale (EQ-5D VAS) that resembles a thermometer, with 0 at the bottom to denote the "worst imaginable health state" and 100 at the top to denote the "best imaginable health state." The EQ-5D was designed to be self-administered, easily understood, and completed in !5 min. The EQ-5D's simplicity is both an asset and a limitation [21] . The developers were willing to sacrifice some depth and breadth of measurement in order to lessen the burden on the respondent. Nevertheless, there is a growing body of evidence that supports the utility and validity of the EQ-5D for a variety of patient populations [19] . In addition, because the EQ-5D is a preference-based measure, its health index outcome measure can be used in the calculation of quality-adjusted life years (QALYs), which can be used in cost-utility analysis (CUA) [22] . CUA is a specific type of cost-effectiveness analysis that allows the incorporation of both length of life and quality of life in the measurement of effectiveness (i.e., QALYs gained).
Clinical indicators. Subjects' most recent CD4 cell counts and HIV-1 virus loads were abstracted from their medical charts. Two dichotomous variables were computed to represent disease severity [23] : (1) CD4 cell count !200 cells/mm 3 versus у200 cells/mm 3 and (2) HIV-1 RNA level of р30,000 copies/ mL versus 130,000 copies/mL. These variables were used to examine the discriminative ability of the self-reported healthstatus scores.
Statistical analysis. Self-reported and chart-abstracted data were entered into a statistical package database (SPSS 9.0 for Windows; SPSS). Cronbach's alpha (a) was calculated to estimate the internal consistency of the multi-item scales of the MOS-HIV [24] . Descriptive analyses were used to characterize the subject sample. The distributions of the study variable values were assessed by means of the Lilliefors test of normality and were found to differ significantly from the predicted Gaussian distributions. Spearman's rho (r) was employed to test for associations during the estimation of correlations, and the MannWhitney U test was used to test differences of paired continuous variables for significance [25] . Receiver-operating characteristic (ROC) curves and area under the ROC curves were calculated to assess the discriminative ability of the instruments. An area under the ROC curve 10.50 indicates a discriminative ability greater than chance [26] . All statistical tests were 2-tailed; results with a P value of !.05 were considered significant.
In testing the discriminative ability in this study, we hypothesized that the health-status scores that predominantly assess aspects of physical or general health would be most strongly associated with the laboratory clinical parameters. Other authors have presented data to support these relationships with regard to the MOS-HIV scale [27, 28] and EQ-5D scores [19, 29] , respectively. Therefore, it was proposed that the EQ-5D index, the EQ-5D VAS, and the MOS-HIV PHS scores would have the greatest ability to discriminate between patient groups stratified by CD4 cell counts and virus load levels. Although the individual MOS-HIV scale scores are reported, the summary scores (i.e., PHS and MHS) of the MOS-HIV and the health index and VAS scores of the EQ-5D were the target of this analysis. 
RESULTS
The participation rate in the study was 199%. Of the 264 HIV-infected persons recruited by the clinic staff to participate in this study, 22 were excluded from the analyses because of failure to meet the inclusion criteria. Characteristics of the 242 subjects who met the inclusion criteria are shown in tables 1 2. The subjects were generally white, middle-aged men with some college or vocational school education, who had yearly incomes !$10,000, and who were receiving government-subsidized health care. Subjects had a wide range of disease severity, as determined by measurements of CD4 cell counts and HIV-1 virus loads.
The median EQ-5D health index score for the subjects was 0.69 (sample range, Ϫ0.32-1.0). The median EQ-5D VAS score for the subjects was 70.0 (sample range, 0.0-100.0; table 3). With regard to the 5 dimensions of the EQ-5D, 12.4% of the subjects reported no health problems, whereas, for the EQ-5D VAS, 3.4% of the subjects rated their own health status as "best imaginable health state" (i.e., a score of 100). Cronbach's a for the 7 multi-item scales of the MOS-HIV ranged from 0.80 to 0.92, which indicated an excellent internal consistency reliability. The median MOS-HIV PHS score was 47.6 (sample range, 25.6-58.8). The median MOS-HIV MHS score was 42.3 (sample range, 23.0-62.3). The mean ‫ע(‬ SD) and median scores and percentages of subjects with minimum and maximum scores for the 9 scales of the MOS-HIV are shown in ). There were no significant associations between 0.220 P p .001 the MOS-HIV MHS scores and either of the clinical health indicators. Table 4 indicates the ability of the 10 scales of the MOS-HIV to discriminate between groups that are characterized by differences in disease severity, as measured by means of laboratory clinical parameters. Scales that assessed primarily physical health attributes generally discriminated between the groups on the basis of either CD4 cell counts (!200 cells/mm 3 vs. у200 cells/mm 3 ) or HIV-1 RNA copies (р30,000 copies/mL vs. 130,000 copies/mL), whereas scales that assessed primarily mental health attributes generally did not discriminate between these groups. Table 5 reports the ability of the 4 broader health-status scores to discriminate between the 2 groups. The EQ-5D health index, EQ-5D VAS, and MOS-HIV PHS scores discriminated between predefined groups on the basis of either CD4 cell counts or HIV-1 virus loads. The areas under the ROC curves for these scores ranged from 0.584 to 0.731. Although the areas under the ROC curves were 10.5 for the MOS-HIV MHS scores, they did not significantly discriminate between the severity groups on the basis of the Mann-Whitney tests.
DISCUSSION
The results of this study provide evidence of the construct validity of the MOS-HIV and EQ-5D. We found that the EQ-5D VAS, EQ-5D health index, and the MOS-HIV PHS scores were consistently significantly correlated with clinical health indicators. The MOS-HIV MHS scores were not significantly correlated with clinical health indicators in our study. Although they were contrary to some findings [29, 30] , our results were consistent with the relationship we hypothesized on the basis of other studies that have showed mental health scale scores to be unrelated to CD4 cell counts or HIV virus loads [17, 27, 28] . This study found that the EQ-5D health index, EQ-5D VAS, and MOS-HIV PHS scores did discriminate between patients by level of HIV disease severity, as measured by CD4 cell count and HIV-1 virus load. The findings that the MOS-HIV MHS and the MOS-HIV scales that assessed primarily mental health attributes were not strongly associated with physical health indicators (i.e., CD4 cell count and virus load) support the importance of assessing mental health along with self-reported and laboratory measures of physical health status.
We did not find substantial ceiling effects occurring with any of the broader health-status measures. Although we found no reports in the peer-reviewed literature regarding ceiling effects with the MOS-HIV summary scores, Holmes et al. suggest that there is the potential for ceiling effects for scales of the MOS-20 that might also apply to the MOS-HIV [18] . We found moderate ceiling effects in 2 of the MOS-HIV scales (the role functioning and social functioning scales) and a floor effect for the role functioning scale. Our findings indicate that the EQ-5D is suitable for the measurement of the health status of HIVinfected subjects since the distribution of the total score is less skewed than in healthier populations. Likewise, our findings reinforce those of other studies [16, 17] that have concluded that the MOS-HIV is highly appropriate for use in measuring health status in this patient population.
There is good reason to consider the use of both instruments in a complementary measurement approach. The MOS-HIV was designed to measure the self-reported health status of HIVinfected patients, whereas the EQ-5D was designed to measure self-reported health status in any population. On the basis of the discriminative ability tested in this study, both instruments have demonstrated validity for use with HIV-infected subjects. These findings suggest that each of the instruments would be of value in monitoring the health status of HIV-infected patients in clinical practice and in clinical or evaluative trials.
Each instrument has its advantages. The MOS-HIV provides individual scale and summary scores that allow for more specific identification of the domains of HRQOL that are affected by HIV infection, AIDS, and/or its treatment. The EQ-5D is brief and it provides a preference-weighted health index score that can be used in economic analyses to inform resource-allocation decisions. In addition, the EQ-5D provides general health status comparability with other patient populations in which it has been used. In conclusion, this study provides evidence of the construct validity of the EQ-5D and the MOS-HIV instruments and suggests that they may be practical tools for the assessment of health status from the patient's perspective.
